Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that all patients in the ongoing Phase III study for the drug candidate AKP02G2 have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback